Shots:
- Samsung Bioepis has signed a confidential settlement and license agreement with Johnson & Johnson for the commercialization of Pyzchiva, its Stelara (ustekinumab) biosimilar in Europe
- Ustekinumab is an IgG1κ monoclonal antibody targeting IL-12 and IL-23. PYZCHIVA, developed by Samsung Bioepis, received European Commission approval as a Stelara biosimilar in April 2024
- PYZCHIVA was introduced in the EU by Sandoz in July 2024 and expanded to a PFS (autoinjector) in May 2025
Ref: Samsung Bioepis | Image: Samsung Bioepis & Johnson & Johnson | Press Release
Related News:- Samsung Bioepis Reports the EC’s approval of Obodence & Xbryk (Biosimilar, Denosumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
